Xenpozyme™ (olipudase alfa-rpcp intravenous infusion)

Xenpozyme (olipudase alfa‑rpcp) is covered for non‑CNS manifestations of ASMD in adults and pediatric patients only for confirmed ASMD type B or A/B (ASM enzymatic assay and mutation testing; Gaucher disease excluded) who have two or more specified non‑CNS signs. Coverage requires prescribing by or consultation with a specialist in genetics/metabolic/lysosomal disorders, adherence to specified weight‑based dosing and escalation (use actual body weight if BMI ≤30; adjusted body weight = (height in m)^2 × 30 if BMI >30), documentation of diagnoses/clinical signs/weight/BMI, and is authorized for 12 months.

"Documentation specifying ASMD subtype (type B or type A/B)."

Sign up to see full coverage criteria, indications, and limitations.